KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc. (KRYS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 31% planned / 69% discretionary
Largest single sale: $3.9M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Krishnan Krish S 12 fills | President and CEO | Sell | 24,480 | $359.42 | $8.8M | 1,369,994 −1.8% of holding | |
| Krishnan Suma 12 fills | President, R&D | Sell | 24,480 | $359.42 | $8.8M | 1,324,619 −1.8% of holding | |
| Krishnan Suma | President, R&D | Sell 10b5-1 | 520 | $354.54 | $184.4K | 1,326,625 −0% of holding | |
| Krishnan Krish S | President and CEO | Sell 10b5-1 | 520 | $354.54 | $184.4K | 1,372,023 −0% of holding | |
| ROSSI DINO A 8 fills | Director | Sell | 25,000 | $329.12 | $8.2M | 74,659 −25.1% of holding | |
| Thomas John Charles | EVP, General Counsel | Sell 10b5-1 | 1,000 | $347.27 | $347.3K | None left | |
| Krishnan Krish S 10 fills | President and CEO | Sell | 24,680 | $308.21 | $7.6M | 1,474,293 −1.6% of holding | |
| Krishnan Suma 10 fills | President, R&D | Sell | 24,680 | $308.21 | $7.6M | 1,402,242 −1.7% of holding | |
| Krishnan Suma | President, R&D | Sell 10b5-1 | 320 | $300.75 | $96.2K | 1,402,835 −0% of holding | |
| Krishnan Krish S | President and CEO | Sell 10b5-1 | 320 | $300.75 | $96.2K | 1,474,933 −0% of holding | |
| Thomas John Charles | EVP, General Counsel | Sell 10b5-1 | 642 | $302.03 | $193.9K | None left | |
| Krishnan Suma 9 fills | President, R&D | Sell | 24,593 | $263.31 | $6.5M | 1,427,159 −1.7% of holding | |
| Krishnan Krish S 9 fills | President and CEO | Sell | 24,517 | $263.28 | $6.5M | 1,499,300 −1.6% of holding | |
| Krishnan Krish S | President and CEO | Sell 10b5-1 | 483 | $257.31 | $124.3K | 1,499,770 −0% of holding | |
| Krishnan Suma | President, R&D | Sell 10b5-1 | 407 | $257.32 | $104.7K | 1,427,748 −0% of holding | |
| ROMANO KATHRYN | Chief Accounting Officer | Sell 10b5-1 | 750 | $267.60 | $200.7K | 22,366 −3.2% of holding | |
| JANNEY DANIEL 2 fills | Director | Sell 10b5-1 | 11,803 | $275.59 | $3.3M | 75,666 −13.5% of holding | |
| JANNEY DANIEL 2 fills | Director | Sell 10b5-1 | 7,741 | $275.63 | $2.1M | 87,734 −8.1% of holding | |
| JANNEY DANIEL | Director | Sell 10b5-1 | 700 | $275.00 | $192.5K | 92,837 −0.7% of holding | |
| JANNEY DANIEL 9 fills | Director | Sell | 37,895 | $266.88 | $10.1M | 37,326 −50.4% of holding | |
| JANNEY DANIEL 8 fills | Director | Sell 10b5-1 | 13,825 | $268.34 | $3.7M | 107,300 −11.4% of holding | |
| ROSSI DINO A 2 fills | Director | Sell | 18,950 | $261.41 | $5.0M | 89,525 −17.5% of holding | |
| ROMANO KATHRYN 7 fills | Chief Accounting Officer | Sell | 12,500 | $272.14 | $3.4M | 29,818 −29.5% of holding | |
| Krishnan Krish S 16 fills | President and CEO | Sell 10b5-1 | 50,000 | $220.15 | $11.0M | 1,507,100 −3.2% of holding | |
| Krishnan Suma 16 fills | President, R&D | Sell 10b5-1 | 50,000 | $220.15 | $11.0M | 1,507,100 −3.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.